Please assess the completion status of the following clinical trial:

Trial Title: A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has body mass index (BMI) greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 32.0 kilogram per meter square (kg/m\^2) at screening.~2. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing.~3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the Investigator or designee.~   * Supine blood pressure is \>=90/40 millimeter of mercury (mmHg) and \<=140/90 mmHg at screening;~  * Supine pulse rate is \>=45 beats per minute (bpm) and \<=100 bpm at screening;~  * QT interval corrected for pulse rate using Fridericia's formula (QTcF) is \<=450 millisecond (msec) (males) or \<=470 msec (females) and ECG findings considered normal or not clinically significant by the Investigator or designee at screening;~  * Estimated creatinine clearance \>=80 milliliter per minute (mL/min) at screening;~  * Liver function tests including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \<=1.5\*the upper limit of normal (ULN) at screening and check-in.~4. Able to swallow multiple tablets.~Exclusion Criteria:~1. Has history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participants by their participation in the study.~2. Has history or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.~3. Has history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.~4. Unable to refrain from or anticipates the use of:~   • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first dosing.~5. Has history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer 354 milliliter (mL)/12 Ounce \[oz\], wine \[118 mL/4 oz\], or distilled spirits \[29.5 mL/1 oz\] per day).~6. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.~7. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.~8. Donation of blood or significant blood loss within 56 days prior to the first dosing.~9. Plasma donation within 7 days prior to the first dosing.~10. Has participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part 1: Soticlestat 300 mg + Itraconazole 200 mg (Type: EXPERIMENTAL): Soticlestat 300 milligram (mg), tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by itraconazole 200 mg solution, orally, once daily from Day 1 up to Day 11, further followed by soticlestat 300 mg tablet, orally along with itraconazole 200 mg solution, orally on the morning of Day in Period 2.
- Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg (Type: EXPERIMENTAL): Soticlestat 300 mg, tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by single dose of mefenamic acid 500 mg capsule (first dose only), orally on the morning of Day 1 and 250 mg subsequent doses at every six hours up to Day 7 in Period 2, further followed by soticlestat 300 mg tablet, orally, followed by mefenamic acid 250 mg capsule, orally in morning of Day 2 in Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).